Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Cyclophosphamide
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
High-field imaging of neurodegenerative diseases.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
Development of the Brief Inventory of Perceived Stress.
A systematic review of research undertaken in vocational rehabilitation for people with multiple sclerosis.
Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis.
Rehabilitation interventions in multiple sclerosis: an overview.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Arzerra receives approval in Japan
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Stress signaling etches heritable marks on chromatin.
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.

Pages